Patent classifications
A61P23/02
PACKAGING BODY FOR PATCH AND METHOD OF PACKING PATCH
To provide a packaging body for a patch exhibiting excellent temporal stability of a drug, a patch product equipped with the patch and a packaging bag, and a method of manufacturing the patch product.
A patch product equipped with a packaging bag formed of a laminate composed of at least three or more layers including a cyclic polyolefin film and a lidocaine- or rivastigmine-containing patch housed in the packaging bag, a method of the patch product, and a packaging body for a patch formed of a laminate including a cyclic polyolefin film.
AROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN DRUG
Disclosed is an aromatic compound. Such compounds can locally produce a long-lasting nerve blocking effect, have an analgesic effect, an anti-pruritic effect, etc., and can be used in the preparation of a long-acting local anaesthetic drug, a local analgesic drug and an anti-pruritic drug.
AROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF IN DRUG
Disclosed is an aromatic compound. Such compounds can locally produce a long-lasting nerve blocking effect, have an analgesic effect, an anti-pruritic effect, etc., and can be used in the preparation of a long-acting local anaesthetic drug, a local analgesic drug and an anti-pruritic drug.
METHODS, AGENTS, AND DEVICES FOR LOCAL NEUROMODULATION OF AUTONOMIC NERVES
Methods, agents, and devices to treat medical conditions through local chemical neuromodulation of the autonomic nervous system are described. Drug formulations may be injected at or near ganglia, nerve plexi, ganglionated plexi, and nerves to treat different diseases. Target sites for the treatment of cardiac and other disease conditions may include extrinsic stellate (cervicothoracic) and cervical ganglia of the sympathetic chain, and intrinsic cardiac nerves and ganglionated plexi innervating the myocardium.
Enhanced solubility drug-containing formulations
This invention describes compositions comprising at least 75 mg/mL of solubilized otherwise poorly soluble drug in an aqueous environment, wherein the composition further comprises a combination of 3 or more acids. Methods of providing analgesia, anti-pyretic effects or reducing pain in a subject presenting with a pain condition, and methods of reducing administration site irritation, inflammation or a combination thereof in a subject presenting with a pain condition, comprising the steps of administering such compositions and infusion pumps containing such compositions are also described.
Enhanced solubility drug-containing formulations
This invention describes compositions comprising at least 75 mg/mL of solubilized otherwise poorly soluble drug in an aqueous environment, wherein the composition further comprises a combination of 3 or more acids. Methods of providing analgesia, anti-pyretic effects or reducing pain in a subject presenting with a pain condition, and methods of reducing administration site irritation, inflammation or a combination thereof in a subject presenting with a pain condition, comprising the steps of administering such compositions and infusion pumps containing such compositions are also described.
VASOCONSTRICTION COMPOSITIONS AND METHODS OF USE
The invention generally relates to compositions for inducing vasoconstriction. The compositions comprise highly selective alpha-2 adrenergic receptor agonists, at low concentrations, such as below 0.05% weight by volume. The compositions preferably comprise brimonidine. The compositions preferably have pH between about 5.5 and about 6.5.
FAST-ACTING TOPICAL ANESTHETIC FORMULATIONS
The present invention relates to formulations of a local anesthetic that provide prompt local anesthesia following topical administration, teaching formulation compositions suitable for administration to the skin that provide onsets of less than one hour. Also disclosed are methods of making the formulations and methods of preventing pain in a subject.
FAST-ACTING TOPICAL ANESTHETIC FORMULATIONS
The present invention relates to formulations of a local anesthetic that provide prompt local anesthesia following topical administration, teaching formulation compositions suitable for administration to the skin that provide onsets of less than one hour. Also disclosed are methods of making the formulations and methods of preventing pain in a subject.
METHOD AND DEVICE FOR TREATING MIGRAINES
A portable device for treatment of migraine having a desktop unit defining an airpath through a desiccant, a heat sink, an air mover and an air outlet, and a tubeset including a tube having one end for connecting to the desktop air outlet and a second end connected to a handheld unit, the handheld unit including a water compartment, and a nebulizer/transducer for introducing water droplets into the air stream. A nasal pillow is provided at the end of the handheld unit for placing against a user's nose.